Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-O!B activators for the treatment of ALS
Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics
Identification of an Anti-diabetic, Orally Available Small Molecule that Regulates TXNIP Expression and Glucagon Action
Thrombospondin-1 regulation of latent TGF-[beta] activation: A therapeutic target for fibrotic disease
SRI36160 is a specific inhibitor of Wnt/[beta]-catenin signaling in human pancreatic and colorectal cancer cells
GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer.
Effects of PD 128763, a New Potent Inhibitor of Poly(ADP-Ribose) Polymerase, on X-Ray-Induced Cellular Recovery Processes in Chinese Hamster V79 Cells
AlphaScreen HTS and live-cell bioluminescence resonance energy transfer (BRET) assays for identification of Tau-Fyn SH3 interaction inhibitors for alzheimer disease
Structure-activity relationships and cellular mechanism of action of small molecules that enhance the delivery of oligonucleotides.
Predicting radiotherapy response for patients with soft tissue sarcoma by developing a molecular signature.
Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations.
Consortia's critical role in developing medical countermeasures for re-emerging viral infections: a USA perspective.
Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma